摘要
目的 对比不同抗凝药物对早期行经皮冠状动脉介入治疗(PCI)术的非ST段抬高型心肌梗死(NSTEMI)高危患者的临床效果。方法 138例早期行PCI术的NSTEMI高危患者,通过随机自愿原则分为观察组和对照组,各69例。对照组采用低分子量肝素钙抗凝,观察组采用磺达肝癸钠抗凝。比较两组患者抗凝指标(凝血酶原时间、凝血酶时间、纤维蛋白原)及出血事件发生率。结果 观察组凝血酶原时间(17.02±3.73)s、凝血酶时间(17.24±3.83)s、纤维蛋白原(2.56±0.75)g/L与对照组的(16.98±3.85)s、(16.14±3.46)s、(2.62±0.74)g/L比较差异无统计学意义(P>0.05)。观察组出血事件发生率2.90%与对照组的4.35%比较,差异无统计学意义(P>0.05)。结论 对早期行PCI术治疗的NSTEMI高危患者通过低分子量肝素钙抗凝和磺达肝癸钠抗凝均可以发挥显著的作用,疗效无差异,可根据患者实际情况合理选择药物。
Objective To compare the clinical effects of different anticoagulants on patients with high-risk non-ST-segment elevation myocardial infarction(NSTEMI) undergoing early percutaneous coronary intervention(PCI). Methods A total of 138 cases of high-risk NSTEMI patients who underwent early PCI were randomly divided into observation group and control group, with 69 cases in each group. The control group was treated with low-molecular-weight heparin calcium for anticoagulation, and the observation group was treated with fondaparinux sodium for anticoagulation. The anticoagulation indexes(prothrombin time, thrombin time,fibrinogen) and the incidence of bleeding events were compared between the two groups. Results The observation group had prothrombin time of(17.02±3.73) s, thrombin time of(17.24±3.83) s, fibrinogen of(2.56±0.75) g/L,which were not statistically significant compared with(16.98±3.85) s,(16.14±3.46) s,(2.62±0.74) g/L in the control group(P>0.05). The incidence of bleeding events in the observation group was 2.90%, which was not statistically significant compared with 4.35% of the control group(P>0.05). Conclusion Anticoagulation with low-molecular heparin calcium and sodium fondaparinux can play a significant role in high-risk NSTEMI patients treated with early PCI, and there is no difference in efficacy. Drugs can be selected based on the actual conditions of the patients.
作者
王辉
WANG Hui(Beipiao Central Hospital,Beipiao 122100,China)
出处
《中国现代药物应用》
2022年第10期108-110,共3页
Chinese Journal of Modern Drug Application
关键词
经皮冠状动脉介入治疗术
非ST段抬高型心肌梗死
低分子量肝素钙
磺达肝癸钠
Percutaneous coronary intervention
Non-ST-segment elevation myocardial infarction
Lowmolecular-weight heparin calcium^(2)Fondaparinux sodium
